CLINICAL TRIAL SIMULATION TO IMPROVE HIV PREEXPOSURE PROPHYLAXIS DOSING IN PREGNANCY
Several studies of pregnant women on TDF/FTC report lower TFV exposures in the 2nd and 3rd trimesters due to pregnancy-related increased volume of distribution and renal clearance. The Partners Demonstration Project showed the largest decline during pregnancy compared to non-pregnant women – 45% to 58% in TFV and active TFV diphosphate concentrations, respectively. We hypothesized…